Shayan Shakeri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shayan Shakeri has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Mahsa Mayeli
Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA
3 shared publications David Gulisashvili
Department of Diagnostic Radiology & Nuclear Medicine University of Maryland School of Medicine Baltimore Maryland USA
2 shared publications- Hamide Nasiri
Student Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2 shared publications - Afra Darvishi
Student research committee, Tabriz University of Medical Sciences, Tabriz, 5166614756, Iran
1 shared publication - Ali Rajabpour Sanati
Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication - Ali Shushtari
Mazandaran University of Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 27086
Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer’s disease
Blood-based biomarkers could broaden access to Alzheimer’s disease diagnostics, but their ability to approximate tau PET, and to address gray-zone results, remains uncertain. We evaluated plasma p-tau217 against tau PET using a harmonized ADNI baseline cohort and an independently derived temporal meta-ROI tau-PET threshold. We included participants with complete baseline plasma biomarkers (p-tau217, Aβ42, Aβ40, NfL, GFAP), tau PET, and demographics, including: cognitively normal = 229, mild cognitive impairment = 149, and Alzheimer’s disease dementia = 41. ROC analyses assessed discrimination of tau-PET positivity overall and by diagnostic group. A two-cutoff strategy was implemented to minimize indeterminate classifications. Across the pooled cohort, p-tau217 demonstrated the strongest ability to discriminate tau-PET status (AUC 0.671, 95% CI 0.597–0.746), outperforming Aβ42, Aβ40, and Aβ42/Aβ40; Though overall accuracy remained moderate and performance differed based on diagnosis, with AUCs of 0.785 for Alzheimer’s disease dementia and lower values for cognitively normal and mild cognitive impairment. The two-cutoff approach substantially reduced intermediate classifications compared with conventional markers. In ADNI, plasma p-tau217 showed the highest discriminative performance among the single blood biomarker for detecting tau-PET positivity, showing moderate accuracy overall and its strongest performance in Alzheimer’s disease dementia. A two-cutoff approach substantially reduces gray-zone classifications, supporting p-tau217 as a primary screening tool before confirmatory imaging. Further work and validation are needed across different groups.
- 8 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 27086
Open AccessPlasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer’s disease
Blood-based biomarkers could broaden access to Alzheimer’s disease diagnostics, but their ability to approximate tau PET, and to address gray-zone results, remains uncertain. We evaluated plasma p-tau217 against tau PET using a harmonized ADNI baseline cohort and an independently derived temporal meta-ROI tau-PET threshold. We included participants with complete baseline plasma biomarkers (p-tau217, Aβ42, Aβ40, NfL, GFAP), tau PET, and demographics, including: cognitively normal = 229, mild cognitive impairment = 149, and Alzheimer’s disease dementia = 41. ROC analyses assessed discrimination of tau-PET positivity overall and by diagnostic group. A two-cutoff strategy was implemented to minimize indeterminate classifications. Across the pooled cohort, p-tau217 demonstrated the strongest ability to discriminate tau-PET status (AUC 0.671, 95% CI 0.597–0.746), outperforming Aβ42, Aβ40, and Aβ42/Aβ40; Though overall accuracy remained moderate and performance differed based on diagnosis, with AUCs of 0.785 for Alzheimer’s disease dementia and lower values for cognitively normal and mild cognitive impairment. The two-cutoff approach substantially reduced intermediate classifications compared with conventional markers. In ADNI, plasma p-tau217 showed the highest discriminative performance among the single blood biomarker for detecting tau-PET positivity, showing moderate accuracy overall and its strongest performance in Alzheimer’s disease dementia. A two-cutoff approach substantially reduces gray-zone classifications, supporting p-tau217 as a primary screening tool before confirmatory imaging. Further work and validation are needed across different groups.
- Open Access
- 22 February 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (3) , e70194
Novel Mutations in KCNJ10 Gene Associated With SeSAME Syndrome: Rare Disorder With Possible Common Mutation
Background: Mutations in the KCNJ10 gene cause SeSAME syndrome, an autosomal recessive disorder characterised by seizures, sensorineural deafness, ataxia, intellectual impairment and electrolyte imbalances. KCNJ10 encodes an inwardly rectifying potassium channel Kir4.1, which is essential for preserving potassium ion homeostasis. Methods: We assessed three Iranian families with SeSAME syndrome–like symptoms through whole‐exome sequencing (WES). Segregation analysis and Sanger sequencing were also used to confirm identified mutations. Additionally, bioinformatic tools were utilised to predict the pathogenicity of the variants. Results: We identified two novel KCNJ10 mutations, c.967 T>C (p.Y323H) and c.352G>A (p.A118T) in three families. While there was no evidence of renal involvement, the probands from these families displayed early‐onset seizures, ataxia, developmental delays and hearing abnormalities. Based on the Kir4.1 protein's structural modelling, the stability of the channel is influenced by both mutations. Precisely, p.A118T alters the transmembrane domain that is critical to channel operation, whereas p.Y323H modifies the cytoplasmic C‐terminal domain, which may compromise intracellular localisation and regulation. Conclusion: Our findings can expand the spectrum of mutations in the KCNJ10 gene and provide insight into the genotype–phenotype correlation in the SeSAME syndrome.
- 22 February 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (3) , e70194
Open AccessNovel Mutations in KCNJ10 Gene Associated With SeSAME Syndrome: Rare Disorder With Possible Common Mutation
Background: Mutations in the KCNJ10 gene cause SeSAME syndrome, an autosomal recessive disorder characterised by seizures, sensorineural deafness, ataxia, intellectual impairment and electrolyte imbalances. KCNJ10 encodes an inwardly rectifying potassium channel Kir4.1, which is essential for preserving potassium ion homeostasis. Methods: We assessed three Iranian families with SeSAME syndrome–like symptoms through whole‐exome sequencing (WES). Segregation analysis and Sanger sequencing were also used to confirm identified mutations. Additionally, bioinformatic tools were utilised to predict the pathogenicity of the variants. Results: We identified two novel KCNJ10 mutations, c.967 T>C (p.Y323H) and c.352G>A (p.A118T) in three families. While there was no evidence of renal involvement, the probands from these families displayed early‐onset seizures, ataxia, developmental delays and hearing abnormalities. Based on the Kir4.1 protein's structural modelling, the stability of the channel is influenced by both mutations. Precisely, p.A118T alters the transmembrane domain that is critical to channel operation, whereas p.Y323H modifies the cytoplasmic C‐terminal domain, which may compromise intracellular localisation and regulation. Conclusion: Our findings can expand the spectrum of mutations in the KCNJ10 gene and provide insight into the genotype–phenotype correlation in the SeSAME syndrome.
- 18 June 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (6) , 1-15
Amino acid patterns predict white matter integrity measures in the brain in patients across the Alzheimer’s disease continuum
Alzheimer’s disease (AD), the leading cause of dementia, poses a growing global health challenge due to its rising prevalence and socioeconomic impact. Investigating metabolic alterations associated with white matter integrity (WMI) could provide critical insights into AD pathogenesis and identify potential therapeutic targets. This cross-sectional study explored the associations between amino acid (AA) profiles, assessed via ultra-high-performance liquid chromatography (UHPLC), and WMI metrics derived from diffusion tensor imaging (DTI) in individuals across the AD continuum. A total of 176 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included and grouped into cognitively normal (CN) individuals (n = 54), patients with mild cognitive impairment (MCI, n = 88), and AD patients (n = 34). WMI was evaluated using DTI-derived metrics, including fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). AA profiling was conducted using an appropriate panel. Regression analyses, adjusted for age, gender, and education, was used to identify significant associations between AA levels and WMI. Distinct AA alterations were associated with white matter microstructural integrity across study groups. In CN individuals, higher levels of arginine, glycine, and threonine correlated with decreased FA and increased MD, indicating reduced white matter integrity. Conversely, in AD patients, aspartate, glutamate, and histidine exhibited opposite associations, showing positive correlations with FA and negative correlations with MD, suggesting potential neuroprotective or compensatory mechanisms. These findings underscore the associations between AA patterns and white matter integrity and their potential role as AD progression markers. Further investigations into these AA metabolism pathways may identify novel biomarkers for early diagnosis and targets for therapeutic interventions.
- 18 June 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (6) , 1-15
Amino acid patterns predict white matter integrity measures in the brain in patients across the Alzheimer’s disease continuum
Alzheimer’s disease (AD), the leading cause of dementia, poses a growing global health challenge due to its rising prevalence and socioeconomic impact. Investigating metabolic alterations associated with white matter integrity (WMI) could provide critical insights into AD pathogenesis and identify potential therapeutic targets. This cross-sectional study explored the associations between amino acid (AA) profiles, assessed via ultra-high-performance liquid chromatography (UHPLC), and WMI metrics derived from diffusion tensor imaging (DTI) in individuals across the AD continuum. A total of 176 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included and grouped into cognitively normal (CN) individuals (n = 54), patients with mild cognitive impairment (MCI, n = 88), and AD patients (n = 34). WMI was evaluated using DTI-derived metrics, including fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). AA profiling was conducted using an appropriate panel. Regression analyses, adjusted for age, gender, and education, was used to identify significant associations between AA levels and WMI. Distinct AA alterations were associated with white matter microstructural integrity across study groups. In CN individuals, higher levels of arginine, glycine, and threonine correlated with decreased FA and increased MD, indicating reduced white matter integrity. Conversely, in AD patients, aspartate, glutamate, and histidine exhibited opposite associations, showing positive correlations with FA and negative correlations with MD, suggesting potential neuroprotective or compensatory mechanisms. These findings underscore the associations between AA patterns and white matter integrity and their potential role as AD progression markers. Further investigations into these AA metabolism pathways may identify novel biomarkers for early diagnosis and targets for therapeutic interventions.
- Open Access
- 26 May 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (5) , e70572
MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [18F] AV45 and FDG PET Imaging
Purpose: Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.Method: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).Findings: The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.Conclusion: Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
- 26 May 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (5) , e70572
Open AccessMicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [18F] AV45 and FDG PET Imaging
Purpose: Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.Method: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).Findings: The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.Conclusion: Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
- Open Access
- 1 May 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 18, 732-738
Potential Mediating Role of Polygenic Hazard Score in the Association Between Neurofilament Light Chain and Default Mode Network Connectivity Across the Alzheimer's Disease Continuum
- 1 May 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 18, 732-738
Open AccessPotential Mediating Role of Polygenic Hazard Score in the Association Between Neurofilament Light Chain and Default Mode Network Connectivity Across the Alzheimer's Disease Continuum
- 8 March 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 251, 108817
Microstructural patterns in substantia nigra subregions are associated with depression and olfactory impairments in Parkinson’s disease
- 8 March 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 251, 108817
Microstructural patterns in substantia nigra subregions are associated with depression and olfactory impairments in Parkinson’s disease